• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    FDC Ltd.
    17 Feb 2025
    477.75
    -1.49%
    Glenmark And FDC Recall Products In US Over Manufacturing Issues
    Glenmark And FDC Recall Products In US Over Manufacturing Issues
    NDTV Profit
    New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling Carvediol tablets in strengths of 25 mg and 12.5 mg in the US, the US health regulator stated.
    Copy LinkShare onShare on Share on Share on
    FDC Ltd. is trading below its 30 day SMA of 487.9
    Glenmark, FDC recall products from US market on manufacturing issues: USFDA
    Business Standard | 17 Feb 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    17 Feb 2025
    2143.00
    -0.49%
    Glenmark Pharmaceuticals share price gains 5% post Q3 Results: Do you own it?
    Glenmark Pharmaceuticals share price gains 5% post Q3 Results: Do you own it?
    livemint
    Stock Market Today: Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared after the market Hours. Do you own it?
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
    Glenmark Pharma Share Price Rises After India Sales Grow 300% In Q3
    NDTV Profit | 17 Feb 2025
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    17 Feb 2025
    Results
    3161.30
    -1.12%
    GlaxoSmithKline Pharmaceuticals shares hits 20% upper circuit as profit jumps fivefold in Q3FY25
    GlaxoSmithKline Pharmaceuticals shares hits 20% upper circuit as profit jumps fivefold in Q3FY25
    livemint
    GlaxoSmithKline Pharmaceuticals shares surged 20% to 2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in net profit to 230 crore and 18% revenue growth to 949.42 crore, benefiting from the absence of one-time charges.
    Copy LinkShare onShare on Share on Share on
    GlaxoSmithKline Pharmaceuticals Ltd. is trading above its 200 day SMA of 2687.9
    GlaxoSmithKline hits 20% upper circuit on posting 400% jump in Q3 PAT
    Business Standard | 17 Feb 2025
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    17 Feb 2025
    Results
    3161.30
    -1.12%
    GSK Pharma Q3 Review: Motilal Oswal Maintains 'Neutral' Stance On The Stock, Hikes Target Price Here's Why
    GSK Pharma Q3 Review: Motilal Oswal Maintains 'Neutral' Stance On The Stock, Hikes Target Price Here's Why
    NDTV Profit
    The current valuation captures the earnings upside. hence Motilal Oswal maintains Neutral rating on SGK Pharma.
    Copy LinkShare onShare on Share on Share on
    GlaxoSmithKline Phar.. has an average target of 2610.00 from 2 brokers.
    logo
    Lupin Ltd.
    16 Feb 2025
    1928.30
    -2.84%
    Lupin Eyes Sustained Growth In US Market With New Launches, Strong Product Pipeline
    Lupin Eyes Sustained Growth In US Market With New Launches, Strong Product Pipeline
    NDTV Profit
    The company is focusing on high-growth segments like injectables and complex generics for growth in US market.
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd.'s price crossed below 30Day SMA today
    logo
    Natco Pharma Ltd.
    15 Feb 2025
    958.20
    -1.54%
    Natco Pharma: Looming gap in earnings
    Business Line
    Earnings miss and shift in focus to long-term growth led to sharp sell-off
    Copy LinkShare onShare on Share on Share on
    Natco Pharma Ltd. has lost -28.90% in the last 1 Year
    logo
    Glenmark Pharmaceuticals Ltd.
    14 Feb 2025
    2143.00
    -0.49%
    Glenmark Pharma clocks Q3 PAT of 348 crore
    Business Line
    The company clocked profit after tax (PAT) for the quarter ended December 31, 2024 at Rs 348 crore
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr
    Glenmark Pharma Q3 results: Net profit down at Rs 348 cr on weak US sales
    Business Standard | 14 Feb 2025 1 more
    Glenmark Pharma Q3 Results: Revenue Rises 35%, Profit Declines
    NDTV Profit | 14 Feb 2025
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    14 Feb 2025
    Results
    3161.30
    -1.12%
    GlaxoSmithKline Pharma Q3 results: Net profit up five-fold at Rs 229 crore
    Business Standard
    GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024. The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement. "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added. The company saw strong performance across key product portfolios during the quarter, the drug firm said. Flagship brands within the genera
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.
    GSK Pharma Q3 Results: Profit Increases Fivefold, Beats Estimates
    NDTV Profit | 14 Feb 2025
    logo
    Shilpa Medicare Ltd.
    14 Feb 2025
    899.90
    -2.09%
    Shilpa Medicare Gets 'Buy' Rating As Systematix Initiates Coverage, Sets Target Price Of Rs 857
    Shilpa Medicare Gets 'Buy' Rating As Systematix Initiates Coverage, Sets Target Price Of Rs 857
    NDTV Profit
    The brokerage believe Shilpa Medicare's differentiated / CRAMS portfolio would help the company to deliver high-teen revenue growth and disproportionate profit expansion.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd.'s price crossed below 30Day SMA today
    logo
    Emcure Pharmaceuticals Ltd.
    14 Feb 2025
    1401.70
    -1.82%
    'Utter nonsense': Shark Tank India 4's Viraj Bahl shares his take on 90-hour work week
    'Utter nonsense': Shark Tank India 4's Viraj Bahl shares his take on 90-hour work week
    Business Today
    His take concurs with that of his fellow Shark Tank India judge and Emcure Pharmaceuticals executive director Namita Thapar.
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. has gained 38.91% in the last 3 Months
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd